Hamburg, Germany, August 8, 2026
Evotec SE has entered a strategic AI-enabled research and development collaboration with Odyssey Therapeutics to accelerate the discovery of next-generation small molecule therapies for autoimmune and inflammatory diseases. The partnership combines Odyssey’s expertise in disease biology with Evotec’s artificial intelligence-driven drug discovery platform, advanced screening technologies, proprietary compound libraries, and machine learning capabilities to identify and validate promising therapeutic candidates targeting diseases with significant unmet medical need. Under the agreement, Evotec will generate and deliver validated hit series across multiple high-value targets, enabling Odyssey to rapidly advance discovery-stage programs toward clinical development. The collaboration reflects the increasing adoption of artificial intelligence, high-throughput experimentation, and data-driven drug discovery to improve research efficiency, shorten development timelines, and identify innovative medicines capable of addressing complex immune-mediated diseases that continue to present major therapeutic challenges worldwide.
AI-Powered Collaboration Targets Autoimmune and Inflammatory Diseases
The newly announced partnership is designed to accelerate early-stage drug discovery by integrating Evotec’s AI-enabled discovery platform with Odyssey Therapeutics’ scientific expertise in autoimmune and inflammatory disease biology. Through the collaboration, researchers will leverage advanced screening technologies, high-throughput experimentation, and machine learning-driven data analysis to identify differentiated small molecule drug candidates across multiple high-value therapeutic targets. The combination of computational drug discovery with experimental validation is expected to improve the identification of promising compounds while reducing the time required to advance potential medicines into preclinical development. Autoimmune and inflammatory disorders continue to affect millions of patients globally, and despite significant therapeutic progress, many diseases remain inadequately treated, creating an ongoing need for innovative therapies capable of delivering improved efficacy and long-term disease control.
Advanced Discovery Platform Supports Next-Generation Therapeutics
At the center of the collaboration is Evotec’s integrated data-driven drug discovery platform, which combines artificial intelligence, proprietary compound libraries, and sophisticated experimental technologies to accelerate therapeutic innovation. By applying machine learning algorithms to extensive biological and chemical datasets, researchers aim to rapidly identify and optimize novel compounds with desirable pharmacological properties. Evotec’s advanced infrastructure will support hit identification, validation, and optimization, generating validated starting points that Odyssey can further develop into differentiated therapeutic candidates. The collaboration also reflects a broader shift across the pharmaceutical industry toward combining computational biology, AI-enabled predictive modeling, and laboratory automation to improve success rates in early drug discovery while increasing operational efficiency. By integrating complementary scientific expertise and advanced digital technologies, both companies seek to generate stronger preclinical candidates for diseases where current treatment options remain limited.
Advertisement
Strategic Partnership Advances AI-Driven Drug Discovery Innovation
The collaboration reinforces Evotec’s long-term strategy of expanding AI-powered research partnerships while supporting biotechnology companies through integrated discovery services. Under the agreement, Evotec will be eligible to receive milestone payments based on the successful delivery of validated hit series for each therapeutic target, aligning financial rewards with scientific progress. Although financial details were not disclosed, the structure emphasizes collaborative value creation through successful research outcomes. For Odyssey Therapeutics, access to Evotec’s discovery infrastructure provides additional capabilities to accelerate its growing immunology pipeline and strengthen the development of novel medicines for autoimmune diseases. More broadly, the partnership highlights how artificial intelligence, machine learning, and advanced computational drug discovery are increasingly transforming pharmaceutical research by enabling scientists to analyze complex biological systems more efficiently and identify promising therapeutic candidates with greater precision. As AI continues to reshape the future of drug discovery, collaborations between technology-driven research organizations and disease-focused biotechnology companies are expected to play an increasingly important role in delivering innovative therapies for patients with serious immune-mediated diseases.
Source: Evotec press release
